Immunocore Selects Genedata to Scale Up Discovery of Novel TCR Therapeutics

September 5, 2024
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, announced today that Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, will use Genedata‘s central Scientific Data Management System (SDMS) to scale up discovery of novel TCR therapeutics.

The Genedata platform, purpose-built for automating R&D workflows for novel therapeutic modalities, offers both structured data management and assay analytics and makes data uniquely accessible for multimodal analysis and AI/ML applications.

“We are pleased that Immunocore has chosen Genedata to digitalize their data management as they work to develop and deliver transformative immunomodulating medicines,” said Othmar Pfannes, Ph.D., President of Genedata. “This underlines once more the quality of our software for innovative biotherapeutics.”

Immunocore will use Genedata’s SDMS to handle and make use of the increasing volume of complex R&D data across Immunocore’s modalities and workflows. The Genedata SDMS is built on Genedata Biologics^® and Genedata Screener^®, designed to maximize data value and streamline processes, leveraging insights to enhance protein engineering and reduce project timelines.

High-quality SDMS is crucial for data integrity, compliance, and accessibility, as well as enhanced decision-making, innovation, and competitive advantage. Genedata continues to demonstrate leadership in providing cutting-edge solutions for scientific data management and supporting biopharmaceutical companies in their quest to deliver life-changing therapies.